Along with collaborators Mark von Zastrow and Brian Shoichet, IND faculty member Jeremy Willsey was awarded a Bold & Basic grant from the UCSF Quantitative Biosciences Institute to investigate new therapeutic targets for autism spectrum disorder by examining the underlying genetics, networks, and molecular pathways involved in these conditions. Watch a short video about their winning project below. Congrats to the research team!
Results Point to ‘Bright Future’ for Understanding Disorder
By Nicholas Weiler on May 3, 2017
Tourette disorder (also known as Tourette syndrome) afflicts as many as one person in a hundred worldwide with potentially disabling symptoms including involuntary motor and vocal tics. However, researchers have so far failed to determine the cause of the disorder, and treatments have only limited effectiveness, in part because the genetics underlying the disorder have remained largely a mystery.
Now, as reported online May 3, 2017, in Neuron, a consortium of top researchers – led by scientists at UC San Francisco, Rutgers University, Massachusetts General Hospital, the University of Florida and Yale School of Medicine – has made a significant advance, identifying the first “high-confidence” risk gene for Tourette disorder as well as three other probable risk... Read more ...
IND faculty Dr. Martin Kampmann outlines a new strategy to investigate neurodegenerative diseases in a Perspective in press at Trends in Molecular Medicine. He co-developed a research platform based on CRISPR technology that enables activation and repression of each gene in human cells. This platform paves the way for a systematic elucidation of cellular factors that control neurodegeneration. Such factors are potential therapeutic targets in neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease. Read more about research in the Kampmann lab.
|Drs. Martin Kampmann and Lisa Gunaydin, both Assistant Professors in the IND, celebrate being named Biohub investigators|
IND faculty Dr. Lisa Gunaydin and Dr. Martin Kampmann were named Chan Zuckerberg Biohub Investigators. They are part of the first cohort of 47 scientists from UCSF, Stanford, and Berkeley to join the Biohub.
The Biohub is a nonprofit research organization with the goal to develop new technologies that transform biomedical research. It is funded by a philanthropic investment of $600 million by Facebook founder Mark Zuckerberg and pediatrician Priscilla Chan.